Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify and provide immediate antiretroviral therapy to a
cohort of HIV-infected individuals with very early HIV infection (estimated date of infection
within the last 90 days). The primary aim of the study is to evaluate whether initiation of
dolutegravir plus emtricitabine/tenofovir during acute/early HIV infection leads to
protection of CD4+ T cells and other immune cells in the peripheral blood and lymphoid tissue
from infection.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Gilead Sciences ViiV Healthcare
Treatments:
Dolutegravir Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir